Form 4: Eterna Therapeutics Director Peter Cicala Acquires Stock Options
SEC Filing
Director Peter Cicala reports acquisition of stock options in Eterna Therapeutics Inc.
Summary
- Peter Cicala, a director of Eterna Therapeutics Inc., filed a Form 4 with the SEC.
- The filing reports a transaction on April 26, 2024, where Cicala acquired stock options to purchase 88,946 shares of Eterna Therapeutics common stock at an exercise price of $1.74.
- The options vest 100% on the one-year anniversary of the grant date and expire on 04/26/2034.
- Following the transaction, Cicala directly owns 88,946 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is a routine grant.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/26/2024 | Date of the stock option transaction. |
| 04/26/2025 | Date the stock options vest. |
| 04/26/2034 | Expiration date of the stock options. |
| 04/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.